Cardiovascular and gastrointestinal consequences of discontinuation with low-dose acetylsalicylic acid therapy in patients with cardiovascular disease

被引：0
|
作者：
Garcia Rodriguez, L. A. [1 ]
Cea Soriano, L. [1 ]
Bueno, H. [2 ]
Lanas, A. [3 ]
Johansson, S. [4 ]
机构：
[1] Ctr Espanol Invest Farmacoepidemiol CEIFE, Madrid, Spain
[2] Hosp Gen Univ Gregorio Maranon, Dept Cardiol, Madrid, Spain
[3] Univ Hosp, CIBERehd, Zaragoza, Spain
[4] AstraZeneca R&D, Molndal, Sweden
来源：
EUROPEAN HEART JOURNAL | 2012年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：495 / 495
页数：1
相关论文
共 50 条
  • [21] Use of low-dose acetylsalicylic acid for cardiovascular disease prevention: A practical, stepwise approach for pharmacists
    Barry, Arden R.
    Semchuk, William M.
    Thompson, Ann
    LeBras, Marlys H.
    Koshman, Sheri L.
    CANADIAN PHARMACISTS JOURNAL, 2020, 153 (03) : 153 - 160
  • [22] Impact of Gastrointestinal Problems on Adherence to Low-Dose Acetylsalicylic AcidA Quantitative Study in Patients with Cardiovascular Risk
    Christina Moberg
    Jørgen Naesdal
    Lars-Erik Svedberg
    Delphine Duchateau
    Nicola Harte
    The Patient: Patient-Centered Outcomes Research, 2011, 4 : 103 - 113
  • [23] Burden of Upper Gastrointestinal Symptoms in Patients Receiving Low-Dose Acetylsalicylic Acid for Cardiovascular Risk Management A Prospective Observational Study
    Bytzer, Peter
    Pratt, Stephen
    Elkin, Eric
    Naesdal, Jorgen
    Sorstadius, Elisabeth
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2013, 13 (01) : 27 - 35
  • [24] Burden of Upper Gastrointestinal Symptoms in Patients Receiving Low-Dose Acetylsalicylic Acid for Cardiovascular Risk ManagementA Prospective Observational Study
    Peter Bytzer
    Stephen Pratt
    Eric Elkin
    Jørgen Næsdal
    Elisabeth Sörstadius
    American Journal of Cardiovascular Drugs, 2013, 13 : 27 - 35
  • [25] Esomeprazole for Prevention and Resolution of Upper Gastrointestinal Symptoms in Patients Treated With Low-dose Acetylsalicylic Acid for Cardiovascular Protection: The OBERON Trial
    Scheiman, James M.
    Herlitz, Johan
    van Zanten, Sander J. Veldhuyzen
    Lanas, Angel
    Agewall, Stefan
    Naucler, Emma C.
    Svedberg, Lars-Erik
    Nagy, Peter
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2013, 61 (03) : 250 - 257
  • [26] Re-prescription of low-dose acetylsalicylic acid therapy after discontinuation: incidence and
    Garcia Rodriguez, L. A.
    Johansson, S.
    Nagy, P.
    Martin-Merino, E.
    EUROPEAN HEART JOURNAL, 2013, 34 : 473 - 473
  • [27] Cardiovascular events after discontinuation of low-dose aspirin
    Pareek, Manan
    Kristensen, Steen D.
    Grove, Erik L.
    JOURNAL OF THORACIC DISEASE, 2018, 10 (01) : 75 - 78
  • [28] LOW-DOSE ACETYLSALICYLIC-ACID AND THROMBOXANE RELEASE AT THE SITE OF PLUG FORMATION INVIVO IN ELDERLY PATIENTS WITH CARDIOVASCULAR-DISEASE
    THORNGREN, M
    ECKERT, B
    VINGE, E
    JOURNAL OF INTERNAL MEDICINE, 1990, 227 (03) : 189 - 193
  • [29] Mortality in patients who discontinue low-dose acetylsalicylic acid therapy after upper gastrointestinal bleeding
    Gonzalez-Perez, Antonio
    Eugenia Saez, Maria
    Johansson, Saga
    Nagy, Peter
    Garcia Rodriguez, Luis A.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 (02) : 215 - 222
  • [30] Prescription rates and adherence to proton pump inhibitor therapy among patients who require low-dose acetylsalicylic acid for cardiovascular prevention
    Herlitz, J.
    Sorstadius, E.
    Naucler, E.
    Naesdal, J.
    EUROPEAN HEART JOURNAL, 2010, 31 : 675 - 676
12345